Potential cardiovascular disease risk markers among HIV-infected women initiating antiretroviral treatment.
about
Pro-Inflammatory Markers in Relation to Cardiovascular Disease in HIV Infection. A Systematic ReviewAngiotensin converting enzyme inhibitor and HMG-CoA reductase inhibitor as adjunct treatment for persons with HIV infection: a feasibility randomized trialMacrophage inflammatory markers are associated with subclinical carotid artery disease in women with human immunodeficiency virus or hepatitis C virus infectionObesity Among HIV-Infected Adults Receiving Medical Care in the United States: Data From the Cross-Sectional Medical Monitoring Project and National Health and Nutrition Examination SurveyEvaluation of cardiovascular biomarkers in a randomized trial of fosamprenavir/ritonavir vs. efavirenz with abacavir/lamivudine in underrepresented, antiretroviral-naïve, HIV-infected patients (SUPPORT): 96-week results.Initiation of antiretroviral therapy at high CD4 cell counts: does it reduce the risk of cardiovascular disease?Soluble CD14 is independently associated with coronary calcification and extent of subclinical vascular disease in treated HIV infection.Monocyte activation from interferon-α in HIV infection increases acetylated LDL uptake and ROS productionT-cell activation, both pre- and post-HAART levels, correlates with carotid artery stiffness over 6.5 years among HIV-infected women in the WIHSImmune activation in HIV-infected aging women on antiretrovirals--implications for age-associated comorbidities: a cross-sectional pilot study.The effect of HAART-induced HIV suppression on circulating markers of inflammation and immune activation.Cardiovascular disease risk in an aging HIV population: not just a question of biology.Is there continued evidence for an association between abacavir usage and myocardial infarction risk in individuals with HIV? A cohort collaboration.Biomarkers of inflammation in HIV-infected Peruvian men and women before and during suppressive antiretroviral therapy.Association of subclinical atherosclerosis with lipid levels amongst antiretroviral-treated and untreated HIV-infected women in the Women's Interagency HIV study.Novel relationships of markers of monocyte activation and endothelial dysfunction with pulmonary dysfunction in HIV-infected persons.Noncalcified coronary atherosclerotic plaque and immune activation in HIV-infected women.Dyslipidemia and cardiovascular risk in human immunodeficiency virus infection.Treatment-related changes in serum lipids and inflammation: clinical relevance remains unclear. Analyses from the Women's Interagency HIV study.Risk of coronary heart disease in patients with HIV infection.Faces of Frailty in Aging with HIV Infection.Cardiovascular disease risk among women living with HIV in North America and Europe.Coagulation imbalance and neurocognitive functioning in older HIV-positive adults on suppressive antiretroviral therapy.Sex Differences in Select Non-communicable HIV-Associated Comorbidities: Exploring the Role of Systemic Immune Activation/Inflammation.
P2860
Q26774828-B3C0AFD7-1120-407B-ABEA-C43E5AEC358AQ28484460-86FAA75C-2F96-4BF9-8B2A-55EF4F78646FQ30405402-E2F94658-2ABB-4C10-B9A2-412853B30506Q30979829-97A04756-691D-41BE-B220-37D967C4208CQ31118978-EAC565B6-10D2-4CF4-B30C-FFC8F92A46E2Q33649200-53020BF1-3876-4245-AFFB-57E79304D054Q33899641-B79FC320-630A-427E-8D7F-2870F7D134D3Q34292033-784833A1-B014-4B5E-925B-2C9C62A33DBFQ34342183-B9D1EC5B-FD93-443C-86D3-EE727DCF29C4Q34749335-93E856D2-F66E-414B-A3C7-88F6D80DDD75Q35030011-BA046B4A-BDC3-43FE-AFD9-EC79DB11EF05Q35064091-B6A7A539-05D7-41D2-B747-FECFA4424754Q35977313-96D07D94-2259-41A1-987C-B92936E7C454Q36775142-A58A8526-C054-4159-8BB9-9551FEFB6AB1Q36967048-0060E293-7515-4BCD-AB78-CDFC684DADEBQ37102014-C3936C7B-85D1-4FB5-A3D3-8D8FB08FC4EAQ37272371-68F81170-D4F7-4739-8E68-2C341B28573CQ37319195-43028DF7-F4B7-466C-B181-68BDD57B4AE2Q37540570-7DEF1A18-44D9-49F8-9600-77739F365812Q38261508-6887A000-B7D6-4363-8F74-F2486312D7A2Q38756258-3AD1B1FC-62CB-4F9D-9373-40D5D0529D00Q40074176-AFA837DD-1FDF-40DD-9DC9-5BB7E2AF619CQ40367422-EEF827E3-035B-4021-ADCF-F204CF0187B4Q47597201-1E2F6C8E-454E-4E97-BE20-271E346CD9A8
P2860
Potential cardiovascular disease risk markers among HIV-infected women initiating antiretroviral treatment.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Potential cardiovascular disea ...... ting antiretroviral treatment.
@ast
Potential cardiovascular disea ...... ting antiretroviral treatment.
@en
type
label
Potential cardiovascular disea ...... ting antiretroviral treatment.
@ast
Potential cardiovascular disea ...... ting antiretroviral treatment.
@en
prefLabel
Potential cardiovascular disea ...... ting antiretroviral treatment.
@ast
Potential cardiovascular disea ...... ting antiretroviral treatment.
@en
P2093
P2860
P1476
Potential cardiovascular disea ...... ting antiretroviral treatment.
@en
P2093
Alan L Landay
Christina M Parrinello
Howard N Hodis
Jason Lazar
Kathryn Anastos
Lorie Benning
Mary Young
Philip J Norris
Phyllis C Tien
Robert C Kaplan
P2860
P304
P356
10.1097/QAI.0B013E31825B03BE
P407
P577
2012-08-01T00:00:00Z